Platform-derived program

About convEyXO

ConvEyXO is a pre-clinical stage biotech developing a scalable platform for RNA-enhanced exosome therapeutics aimed at degenerative diseases. The company's core technology involves proprietary methods for producing, purifying, and loading exosomes derived from an immortalized mesenchymal stem cell line, aiming for potency, consistency, and dramatically lower manufacturing costs. With a focus on extending healthspan by addressing inflammatory and age-related conditions, ConvEyXO is building a pipeline targeting musculoskeletal and metabolic degenerative diseases. The company is privately held, pre-revenue, and founded by experts in cell therapy and advanced manufacturing.

About convEyXO

ConvEyXO is a pre-clinical stage biotech developing a scalable platform for RNA-enhanced exosome therapeutics aimed at degenerative diseases. The company's core technology involves proprietary methods for producing, purifying, and loading exosomes derived from an immortalized mesenchymal stem cell line, aiming for potency, consistency, and dramatically lower manufacturing costs. With a focus on extending healthspan by addressing inflammatory and age-related conditions, ConvEyXO is building a pipeline targeting musculoskeletal and metabolic degenerative diseases. The company is privately held, pre-revenue, and founded by experts in cell therapy and advanced manufacturing.

Therapeutic Areas